Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 Targets

    Question

    Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 Targets

    Direct answer

    DENTSPLY SIRONA exceeded Q2 profit expectations with adjusted EPS of $0.52 compared to $0.36 consensus, despite overall quarterly revenue falling 4.1% year-over-year. Management maintained full-year 2026 financial guidance for net sales between $3.5 billion and $3.6 billion and adjusted EPS of $1.40 to $1.50, supported by 7.1% growth in its Wellspect Healthcare business.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 Targets”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-eps-estimates-at-0-52-and-reaffirms-fy2026-targets-c80436

    EQUITY
    Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 Targets
    DENTSPLY SIRONA exceeded Q2 profit expectations with adjusted EPS of $0.52 compared to $0.36 consensus, despite overall quarterly revenue falling 4.1% year-over-year. Management maintained full-year 2026 financial guidance for net sales between $3.5 billion and $3.6 billion and adjusted EPS of $1.40 to $1.50, supported by 7.1% growth in its Wellspect Healthcare business.
    XRAY
    Impact
    65
    SEP 9
    SIG
    85%
    XRAY
    Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 Targets
    DENTSPLY SIRONA exceeded Q2 profit expectations with adjusted EPS of $0.52 compared to $0.36 consensus, despite overall quarterly revenue falling 4.1% year-over-year. Management maintained full-year 2026 financial guidance for net sales between $3.5 billion and $3.6 billion and adjusted EPS of $1.40 to $1.50, supported by 7.1% growth in its Wellspect Healthcare business.
    → Healthcare consumable segment revenue growth of 7.1% offsets cyclical dental equipment declines, sustaining full-year operating earnings targets of $1.40 to $1.50 per share for XRAY.
    Impact
    DENTSPLY SIRONA exceeded Q2 profit expectations with adjusted EPS of $0.52 compared to $0.36 consensus, despite overall quarterly revenue falling 4.1% year-over-year. Management maintained full-year 2026 financial guidance for net sales between $3.5 billion and $3.6 billion and adjusted EPS of $1.40 to $1.50, supported by 7.1% growth in its Wellspect Healthcare business.
    Affected
    XRAY
    Transmission
    Healthcare consumable segment revenue growth of 7.1% offsets cyclical dental equipment declines, sustaining full-year operating earnings targets of $1.40 to $1.50 per share for XRAY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYhealthcare consumable sales resilience offsetting equipment revenue declinesMixed1-4wQ2 EPS reached $0.52 vs $0.36 consensus; full-year EPS guidance reaffirmed at $1.40-$1.50.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYMixed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month